Biofrontera Inc. $BFRI

By Microcap Ledger desk · CIK 0001858685

Facts as of Oct 11, 2026, 08:16 AM UTC. Built from SEC filings and our own data. Small caps move fast; check the latest filings.

Snapshot

Exchange: Nasdaq Capital Market
Sector: Pharmaceutical Preparations
Headquarters: Woburn, MA
Fiscal year end: December 31
Shares outstanding: 14,852,359 [10-Q 2026-08-13]
as of 2026-08-11

Sources: [10-K 2026-03-19]

What the company doesAI summary of filing

Biofrontera Inc. is a biopharmaceutical company that develops, manufactures, and commercializes pharmaceutical products for dermatological conditions, with a focus on photodynamic therapy. The company sells Ameluz and RhodoLED Lamp series products directly to dermatology offices and groups for treating actinic keratosis, a common precancerous skin condition. The company generates revenue through direct sales to dermatologists in the United States. As of the filing date, the company is revenue-generating with ongoing research and development programs focused on label expansion for Ameluz and improving RhodoLED Lamp capabilities. [10-K 2026-03-19]

Segments: Ameluz, RhodoLED Lamps (BF-RhodoLED and RhodoLED XL)

Financial health

From XBRL company facts (USD)
Period	Revenue	Net income	Operating cash flow	Cash	Filing
6 months to Jun 2026	$22.09M	−$5.36M	−$1.73M	$4.66M	[10-Q 2026-08-13]
FY ended Dec 2025	$41.70M	−$10.54M	−$13.36M	$6.39M	[10-K 2026-03-19]
FY ended Dec 2024	$37.32M	−$17.76M	−$10.27M	$5.91M	[10-K 2026-03-19]

Quarterly cash burn: −$864.0K
Cash runway Estimate: ~16.2 months

Capital structure and dilution

Summary only. How these instruments work: Dilution & financing desk.

Share count
Date	Shares outstanding	Filing
2024-11-12	7,749,211	[10-Q 2024-11-14]
2025-03-19	8,873,932	[10-K 2025-03-20]
2025-05-13	9,446,197	[10-Q 2025-05-15]
2025-08-12	10,668,442	[10-Q 2025-08-13]
2025-11-10	11,648,323	[10-Q 2025-11-12]
2026-03-16	11,648,323	[10-K/A 2026-07-22]
2026-05-13	12,803,344	[10-Q 2026-05-14]
2026-08-11	14,852,359	[10-Q 2026-08-13]

Shelf registration: S-1 filed 2025-12-05; declared effective 2025-12-19 [S-1 2025-12-05]

Listing status

Current status: 4 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-01-07. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.

Date	Event	Details	Deadline	Filing
2026-01-07	8-K Item 3.01	Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing	—	[8-K 2026-01-07]
2025-05-23	8-K Item 3.01	Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing	—	[8-K 2025-05-23]
2025-05-14	8-K Item 3.01	Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing	—	[8-K 2025-05-14]
2024-11-27	8-K Item 3.01	Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing	—	[8-K 2024-11-27]

More on deficiency notices and uplistings: Listing status desk.

Who owns it

Recent Form 4 transactions
Date	Insider	Type	Shares	Price	Filing
2026-07-28	Luebbert Hermann	exercise	62,500	—	[4 2026-07-29]
2026-07-28	Leffler Eugene Frederick	exercise	31,250	—	[4 2026-07-29]
2026-03-05	Luebbert Hermann	exercise	137,500	—	[4 2026-03-06]
2026-03-05	Leffler Eugene Frederick	exercise	87,500	—	[4 2026-03-06]

Catalysts and calendar

Recent filings and releases
Date	Type	Title
2026-09-14	8-K	Other events
2026-08-13	10-Q	Quarterly report
2026-08-13	8-K	Results of operations
2026-08-12	13G/A	Beneficial ownership report (5%+ holder)
2026-07-22	10-K/A	Amended report
2026-06-17	8-K	Shareholder vote results
2026-05-14	10-Q	Quarterly report
2026-05-14	8-K	Results of operations
2026-04-30	DEF 14A	Proxy statement
2026-03-19	10-K	Annual report
2026-03-19	8-K	Results of operations
2026-03-09	8-K	Regulation FD disclosure

Facts as of Oct 11, 2026, 08:16 AM UTC. Small caps move fast; check the latest filings.